Crinetics Pharmaceuticals, Inc. (CRNX)
84.95
0.00 (0.00%)
Inactive · Last trade price on Aug 31, 2026
Crinetics Pharmaceuticals Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 42.16 | 7.7 | 1.04 | 4.01 | 4.74 | 1.08 |
Revenue Growth | 2928.45% | 640.71% | -74.11% | -15.28% | 339.43% | 1418.31% |
Gross Profit Gross Profit Growth | -334.72 | -325.44 | -239.12 | -164.51 | -125.49 | -83.18 |
Operating Income Operating Income Growth | -549.09 | -516.77 | -338.85 | -222.61 | -167.88 | -107.7 |
Net Income Net Income Growth | -501.61 | -465.32 | -298.41 | -214.53 | -163.92 | -107.64 |
Earnings Per Share EPS Growth | -5.03 | -4.95 | -3.69 | -3.69 | -3.15 | -2.80 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Product Net Product Net Growth | - | 5.42 | - | - |
Collaboration and License Collaboration and License Growth | 2.9 | 2.28 | 1.04 | 4.01 |
Revenue (Total) Revenue (Total) Growth | 42.16 | 7.7 | 1.04 | 4.01 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,206 | 1,028 | 1,354 | 558.56 | 334.43 | 333.71 |
Total Debt Total Debt Growth | 47.19 | 48.54 | 51.72 | 51.73 | 3.08 | 4.01 |
Net Cash (Debt) Net Cash Growth | 1,159 | 979.35 | 1,302 | 506.83 | 331.35 | 329.69 |
Net Cash Growth | 1.06% | -24.80% | 156.96% | 52.96% | 0.50% | 98.57% |
Net Cash Per Share Net Cash Per Share Growth | 11.61 | 10.41 | 16.12 | 8.73 | 6.37 | 8.58 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -422.52 | -377.92 | -230.19 | -168.6 | -115.21 | -88.59 |
Capital Expenditures CapEx Growth | -2.66 | -5.76 | -3.84 | -4.69 | -1.66 | -0.44 |
Free Cash Flow Free Cash Flow Growth | -425.18 | -383.68 | -234.04 | -173.29 | -116.86 | -89.02 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Margin | -1302.52% | -6714.77% | -32613.47% | -5547.17% | -3544.06% | -9990.91% |
Pretax Margin | -1189.45% | -6043.88% | -28720.69% | -5345.85% | -3460.38% | -9985.25% |
Profit Margin | -1189.88% | -6046.22% | -28720.69% | -5345.85% | -3460.38% | -9985.25% |
FCF Margin | -1008.58% | -4985.50% | -22525.31% | -4318.12% | -2466.98% | -8258.26% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 213.74 | 573.96 | 4563.69 | 592.26 | 207.88 | 1242.80 |